September 27, 2010 – A post-market study investigating a new treatment for peripheral artery disease of the superficial femoral artery (SFA) has completed enrollment.

The VIPER study, which is looking at the performance of the Gore Viabahn endoprosthesis with a heparin bioactive surface, enrolled 120 patients.

September 27, 2010 — A new plug-in quickly and easily assesses clinically relevant parameters for abdominal aortic aneurysm (AAA) stent planning.

September 27, 2010 – A premarket approval (PMA) application has been submitted for the Formula balloon-expandable stent to help treat patients suffering from renal artery stenosis. Cook Medical’s submission to the U.S. Food and Drug Administration (FDA) included data from the REFORM trial.

September 27, 2010 - Treating varicose veins with a new access kit reduces the number of steps and reduces procedure time. The .018-inch nitinol long-access wire for the VenaCure EVLT system, by AngioDynamics, reduces the number of components involved.

September 27, 2010 – Designed for productivity and versatility, the new GE Healthcare Innova 3100-IQ (Optima Edition) is a reliable, cost-effective, high-performance interventional combo lab for treating a wide variety of patients. It addresses diverse interventional cardiology and interventional radiology needs with one system. The system was unveiled at TCT 2010.

September 24, 2010 - Trial data have established the safety of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndrome. Results from the LANCELOT ACS trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting in Washington, D.C.

The study looked at atopaxar, by Eisai Pharmaceuticals.

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in the femoropopliteal artery. Data from the ZILVER PTX trial demonstrate that paclitaxel-eluting stents had significantly better 12-month patency rates compared to traditional angioplasty with bare-metal stents for lesions in the femoropopliteal artery (above the knee).

September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when compared to paclitaxel-eluting stents.

September 24, 2010 - The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique is safe and feasible. The results of the study, which used the CorPath 200 by Corindus Vascular Robotics, were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting.

September 24, 2010 - The New England Journal of Medicine has published the results of from a trial looking at the treatment of severe aortic stenosis.

The results from cohort B of the Partner trial, which studied the Edwards Sapien transcatheter heart valve, successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now